Filtered By:
Condition: SARS
Countries: USA Health

This page shows you your search results in order of date.

Order by Relevance | Date

Total 92 results found since Jan 2013.

Explainer: Why the U.S. has banned funding for Chinese lab at center of pandemic origin dispute
In a move that has more symbolic than practical impact, the U.S. Department of Health and Human Services (HHS) has imposed new sanctions on a Chinese lab at the center of the debate about the origin of the COVID-19 pandemic. A nine-page HHS memo made public by a House subcommittee that ’s investigating the pandemic ’s origin suspends and proposes debarment of the Wuhan Institute of Virology (WIV) “from participating in United States Federal Government procurement and nonprocurement programs.” In effect, this bars WIV from receiving U.S. government funding now and possibly ever. The ...
Source: ScienceNOW - July 20, 2023 Category: Science Source Type: news

Controller therapy attenuates asthma exacerbations associated with prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children
Nearly 80% of asthma exacerbations are associated with viral respiratory infections.1 The first cases of coronavirus disease 2019 (COVID-19) because of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started in late December 2019 in Wuhan, People's Republic of China, and was first reported in the United States in January 2020.2
Source: Annals of Allergy, Asthma and Immunology - June 12, 2023 Category: Allergy & Immunology Authors: Iris Kim, Tricia Morphew, Christine Chou, Louis Ehwerhemuepha, Stanley Galant Tags: Letters Source Type: research

The COVID-19 virus mutated to outsmart key antibody treatments. Better ones are coming
In 2020, as the COVID-19 pandemic raged and other effective drugs were elusive, monoclonal antibodies (mAbs) emerged as a lifesaving treatment. But now, 3 years later, all the approvals for COVID-19–fighting antibodies have been rescinded in the United States, as mutations of the SARS-CoV-2 virus have left the drugs—which target parts of the original virus—ineffective. Researchers around the globe are now trying to revive antibody treatments by redesigning them to take aim at targets that are less prone to mutation. “There are new approaches that present a much more challenging task for the virus to evade,” ...
Source: ScienceNOW - May 24, 2023 Category: Science Source Type: news

NIH restarts bat virus grant suspended 3 years ago by Trump
Three years after then-President Donald Trump pressured the National Institutes of Health (NIH) to suspend a research grant to a U.S. group studying bat coronaviruses with partners in China, the agency has restarted the award. The new 4-year grant is a stripped-down version of the original grant to the EcoHealth Alliance, a nonprofit research organization in New York City, providing $576,000 per year. That 2014 award included funding for controversial experiments that mixed parts of different bat viruses related to severe acute respiratory syndrome (SARS), the coronavirus that sparked a global outbreak in 2002–04, a...
Source: ScienceNOW - May 8, 2023 Category: Science Source Type: news

Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19
CONCLUSION: Amubarvimab plus romlusevimab was safe and significantly reduced the risk for hospitalization and/or death among nonhospitalized adults with mild to moderate SARS-CoV-2 infection at high risk for progression to severe disease.PRIMARY FUNDING SOURCE: National Institute of Allergy and Infectious Diseases of the National Institutes of Health.PMID:37068272 | DOI:10.7326/M22-3428
Source: Annals of Internal Medicine - April 17, 2023 Category: Internal Medicine Authors: Teresa H Evering Kara W Chew Mark J Giganti Carlee Moser Mauricio Pinilla David Alain Wohl Judith S Currier Joseph J Eron Arzhang Cyrus Javan Rachel Bender Ignacio David Margolis Qing Zhu Ji Ma Lijie Zhong Li Yan Ulises D'Andrea Nores Keila Hoover Bharat Source Type: research

Now in charge, House Republicans launch flurry of investigations
The new Republican majority in the U.S. House of Representatives is preparing to shine a bright light on science—and scientists. This week, it created two investigative panels that will scrutinize the country’s relationship with China and its response to the COVID-19 pandemic. Both committees are expected to grill many prominent scientists and federal research officials on their actions over the past several years. In approach and style, however, they are likely to be very different. The China panel, officially the Select Committee on Strategic Competition between the United States and the Chinese Communist Party,...
Source: Science of Aging Knowledge Environment - January 13, 2023 Category: Geriatrics Source Type: research

Dr. Anthony Fauci Is Stepping Down. Here ’s His Advice For His Successor
After Dr. Anthony Fauci steps down as head of the National Institute of Allergy and Infectious Diseases (NIAID) and chief medical advisor to President Biden on Dec. 31, he’ll leave behind a long and storied career. Ahead of his last day, he spoke to TIME from his office at the National Institutes of Health about what’s next for him—and his advice for whoever fills his shoes. This interview has been edited and condensed for clarity. TIME: You’re leaving your leadership positions in the federal government, but you aren’t retiring. What are you calling the next stage in your career? [time-brightc...
Source: TIME: Health - December 20, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

U.S. weighs crackdown on experiments that could make viruses more dangerous
.news-article__hero--featured .parallax__element{ object-position: 50% 40%; -o-object-position: 50% 40%; } .scroll-wrapper { overflow-x: auto; } .scroll-wrapper .news-article__figure__image{ width: 2680px; max-width: none; padding-bottom: .75rem; } .scroll-fade-before, .scroll-fade-after { position: absolute; width: 1.5rem; transition-duration: .1s; opacity: 1; } .scroll-fade-before { left: 1rem; /*margin-left: -1px;*/ background: linear-gradient(90deg, #fff, #fff 35%, hsla(0, 0%, 100%, 0)); } .scroll-fade-after { right: 1rem; /*margin-right: -1px;*/ background: linear-gradient(270deg, #fff, #fff 35%, hsla(0,...
Source: ScienceNOW - October 19, 2022 Category: Science Source Type: news

Split dosing of coronavirus disease 2019 vaccines provides noninferior antibody responsiveness to conventional vaccine dosing
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused an acute respiratory disease pandemic, termed coronavirus disease 2019 (COVID-19), that has resulted in considerable mortality and morbidity in the United States since early 2020.1 Several vaccines, including the use of messenger RNA (mRNA) vaccines, have proven to be effective against the multiple variant strains of COVID-19,2-5 and therefore, widespread vaccination of the public remains imperative. For patients with a history of allergic reaction to a previous COVID-19 vaccine, a graded administration protocol represents an option, with limited studies s...
Source: Annals of Allergy, Asthma and Immunology - September 6, 2022 Category: Allergy & Immunology Authors: Amal Musa, Macy Wood, Andrew Rorie, Sara M. May, Joel Van De Graaff, Jill A. Poole Tags: Letters Source Type: research

Anthony Fauci, loved and hated, plots his next move: ‘I'm not going to sit in my house’
In 1984, when Anthony Fauci took over as head of the National Institute of Allergy and Infectious Diseases (NIAID), his wife gave him a plant for the new office. Both the palm and the 81-year-old physician are still there, the giant plant now crowding the office of one of the most celebrated—and polarizing—scientific figures in U.S. history. But not for much longer. Fauci announced on 22 August that he would step down at the end of the year from both NIAID and his post as the chief medical adviser to President Joe Biden. “What am I going to do with this plant? It’s a monster. I can’t fit it in any other plac...
Source: ScienceNOW - September 1, 2022 Category: Science Source Type: news